IGFBP2 and rhabdomyosarcoma: Insulin-like growth factor binding protein 2 has been proposed as a potential biomarker in various cancer types, including gliomas (10–18), prostate (19–27), ovarian (28–33) colorectal (34–40) and acute myeloid leukemia (13, 41, 42), acute lymphoblastic leukemia (43, 44) pancreatic (45–48), lung (49–52), cervical cancer (53), breast (54, 55) including triple negative breast cancer (56), liver (57–60), head and neck (61), rhabdomyosarcoma (62), non-seminomatous germ cell cancer (63), gastric (64), synovial sarcoma (65), adrenocortical (66), and Wilm’s tumors (67).